EQS-News: Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive
In October, the CMS published its “Final Rule” updating payment rates and policies for the PPS for end-stage renal disease (ESRD), for the calendar year 2023.
- In October, the CMS published its “Final Rule” updating payment rates and policies for the PPS for end-stage renal disease (ESRD), for the calendar year 2023.
- Renazorb utilizes a proprietary nanoparticle technology being developed by Unicycive for the treatment of hyperphosphatemia in CKD patients on dialysis.
- Renazorb also has an added convenience for patients since it is swallowed with water instead of having to be chewed.
- “Gaining early patient access and reimbursement for newly launched branded drugs can be a challenge” stated Doug Jermasek, Executive Vice President at Unicycive.